Cover Image
市場調查報告書

醫藥品領導者系列 - 前25名眼科用藥物廠商的分析 (2018∼2028年):視網膜疾病、過敏、發炎與感染、青光眼、乾眼症藥物

Pharma Leader Series - Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs

出版商 Visiongain Ltd 商品編碼 294342
出版日期 內容資訊 英文 223 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品領導者系列 - 前25名眼科用藥物廠商的分析 (2018∼2028年):視網膜疾病、過敏、發炎與感染、青光眼、乾眼症藥物 Pharma Leader Series - Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs
出版日期: 2018年07月19日 內容資訊: 英文 223 Pages
簡介

全球眼科藥物市場規模在2017年達到230億美金,其中39.1%被視網膜疾病相關產品所佔據。

本報告提供全球眼用藥物市場相關分析,彙整了市場整體結構和趨勢、主要市場促進及抑制要素、市場規模的動向預測 (今後10年份)、各產品種類與疾病及各地區的詳細趨勢、市場向心力、全球各地的主要製造商 (共25家) 及新興企業簡介(收益額預測、臨床實驗的進展、SWOT分析)等資料,為您概述為以下內容。

第1章 報告概要

第2章 眼用藥物概略

  • 製藥產業概要
  • 全球眼病患的負擔額
  • 眼用藥物:市場詳情
  • 青光眼
    • 疾病診斷與治療方法
  • 老年性黃斑部病變 (AMD)
  • 糖尿病視網膜病變 (DR)
  • 眼睛過敏及過敏性結膜炎
  • 眼部發炎
  • 眼部感染
  • 乾眼症
  • 臨床實驗階段

第3章 全球眼用藥物市場

  • 全球眼用藥物市場最新趨勢
  • 銷售額的預測 (未來11年份)
  • 代表性眼用藥物
  • 眼用藥物市場代表性企業
    • 前25大眼用藥物製造商
  • 眼用藥物市場詳情:銷售額的預測 (未來11年份)
    • 視網膜疾病眼用藥物
    • 眼部過敏、眼部發炎、眼部感染藥物
    • 青光眼藥物
    • 乾眼症藥物
    • 其他眼用藥物
  • 市場佔有率的變化預測
  • 全球眼科用藥物推動、阻礙市場要素
    • 推動市場要素
    • 阻礙市場要素

第4章 美國的代表性眼用藥物廠商

  • Allergan
    • 產品系列
    • 臨床試驗最後階段的候補藥物
    • 銷售額的預測 (未來11年份)
    • SWOT分析
  • Pfizer
  • Regeneron
  • Akorn

第5章 歐洲的代表性眼用藥物廠商

  • Bayer
  • Novartis (包含Alcon)
  • Roche

第6章 亞洲的代表性眼用藥物廠商

  • 參天製藥
  • 千壽製藥
  • Valeant

第7章 新興眼用藥物廠商

  • 具備小規模產品系列及有望候補藥物的企業
  • Acucela
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics (AKB 9778)
  • Alimera Sciences (Iluvien、NADPH Oxidase抑制劑)
  • Amakem
  • Ampio Pharmaceuticals
  • Chengdu Kanghong Pharmaceutical
  • Eleven Biotherapeutics
  • EyeGate Pharmaceuticals
  • Gene Signal (Aganirsen)
  • Icon Bioscience
  • MacuCLEAR (MC 1101)
  • Neurotech
  • Omeros
  • OphthaliX (Can-Fite BioPharma)
  • Ophthotech (Fovista、Zimura)
  • 大塚製藥
  • pSivida Corp.
  • RXi Pharmaceuticals
  • Shire (Lifitegrast (SHP606)、Premiplex (SHP607))
  • ThromboGenics (Jetrea (ocriplasmin)、ThromboGgenics)

第8章 眼用藥物市場定性分析

  • 波特的五力分析:眼用藥物市場
    • 與同樣其他公司的競爭:中
    • 新加入企業的威脅:低
    • 供應商談判力:低
    • 買主的購買力:中
    • 替代產品的威脅:中

第9章 結論

  • 眼用藥物:成長中的利基市場
  • 全球眼用藥物市場
    • 代表性部門、產品與企業
  • 眼用藥物市場的未來預測 (未來11年份)
  • 眼用藥物市場的未來樣貌
    • 市場收益額集中於專業公司
    • 學名藥的普及
    • 小企業帶來大影響的可能性
    • 在眼用藥物市場勝出的企業
  • 用語一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0324

The global ophthalmic drugs market was valued at $23bn in 2017. The market was dominated by the Retinal Disorder drug submarket which held 39.1% of the global ophthalmic drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 223-page report you will receive 83 tables and 71 figures- all unavailable elsewhere.

The 223-page report provides clear detailed insight into the top ophthalmic drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global ophthalmic drugs market revenue forecasts from 2018-2028

Global ophthalmic drugs market revenue orecasts from 2018-2028, by submarket:

  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs

Revenue forecasts from 2018-2028 of the leading ophthalmic drugs:

  • Alphagan
  • Avastin
  • Azopt
  • Eylea
  • Lucentis
  • Lumigan & Ganfort
  • Other Ophthalmic Drugs
  • Restasis
  • Vigamix
  • Xalatan/Xalacom

Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:

  • Acucela
  • Akorn
  • Alimera Sciences
  • Allergan
  • Amakem
  • Bayer
  • Chengdu Kanghong
  • EyeGate Pharmaceuticals
  • Gene Signal
  • Icon Biosciences
  • MacuCLEAR
  • Neurotech
  • Novartis
  • Omeros
  • Ophthotech
  • Otsuka Pharmaceutical
  • Pfizer
  • pSivida Corp.
  • Regeneron
  • Roche
  • Santen
  • Senju
  • Shire
  • ThromboGenics
  • Valeant

Our report provides an overview, revenue forecast from 2018-2028 of the ophthalmic drugs segment, revenue forecast from 2018-2028 of the leading drugs, product pipeline and SWOT Analysis, for these companies:

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • Bayer
  • Novartis
  • Pfizer
  • Regeneron
  • Roche
  • Santen
  • Senju
  • Valeant

Our report provides these Qualitative Analysis:

  • Drivers and Restraints of the Global Ophthalmic Drugs market
  • SWOT Analysis of selected leading companies
  • Porter's Five Forces Analysis of the Global Ophthalmic Drugs Market

Visiongain's study is intended for anyone requiring commercial analyses for the ophthalmic drugs market. You find data, trends and predictions.

Buy our report today ‘Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018-2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Ophthalmic Drugs Market Overview
  • 1.2. Global Ophthalmic Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Ophthalmic Drugs

  • 2.1. The Pharmaceutical Industry: Very Brief Overview
  • 2.2. The Global Burden of Eye Disease
  • 2.3. Ophthalmic Drugs: Market Segmentation
  • 2.4. Glaucoma: the ‘Silent Thief of Sight'
    • 2.4.1. A Classification of Glaucoma
    • 2.4.2. Risk Factors for Glaucoma
    • 2.4.3. Diagnosis of Glaucoma
    • 2.4.4. Drug Treatment of Glaucoma
    • 2.4.5. Laser Treatment and Surgery for Glaucoma
  • 2.5. Age-Related Macular Degeneration (AMD)
    • 2.5.1. Dry (Non-Exudative) AMD
    • 2.5.2. Wet (Exudative) AMD
    • 2.5.3. Risk Factors for AMD
    • 2.5.4. Diagnosis of AMD
    • 2.5.5. Treatment of AMD
  • 2.6. Diabetic Retinopathy (DR)
    • 2.6.1. Diagnosis of Diabetic Retinopathy
    • 2.6.2. Treatment of Diabetic Retinopathy
  • 2.7. Ocular Allergy and Allergic Conjunctivitis
    • 2.7.1. Diagnosis of Ocular Allergy
    • 2.7.2. Treatment of Ocular Allergy
  • 2.8. Ocular Inflammatory Disease
    • 2.8.1. Treatment of Ocular Inflammatory Disease
  • 2.9. Eye Infections
    • 2.9.1. Treatment of Eye Infections
  • 2.10. Dry Eye Syndrome
    • 2.10.1. Treatment of Dry Eye Syndrome
  • 2.11. Phases of Clinical Trials

3. Ophthalmic Drugs: World Market 2018-2028

  • 3.1. The World Ophthalmic Drugs Market in 2018
  • 3.2. World Ophthalmic Drugs Market: Sales Forecast 2018-2028
  • 3.3. Leading Ophthalmic Drugs
  • 3.4. Leading Companies in the Ophthalmic Drugs Market
    • 3.4.1. Top 25 Ophthalmic Drug Manufacturers
  • 3.5. Ophthalmic Drugs Market Segments: Sales Forecasts 2018-2028
    • 3.5.1. Retinal Disorders Drugs Market: Sales Forecast 2018-2028
    • 3.5.2. Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2018-2028
    • 3.5.3. Glaucoma Drugs Market: Sales Forecast 2018-2028
    • 3.5.4. Dry Eye Drugs Market: Sales Forecast 2018-2028
    • 3.5.5. Other Ophthalmic Drugs Market: Sales Forecast 2018-2028
  • 3.6. How Will Market Shares Change to 2028?
  • 3.7. World Ophthalmic Drugs Market: Drivers and Restraints 2018-2028
    • 3.7.1. World Ophthalmic Drugs Market: Analysis of Drivers
    • 3.7.2. World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2018-2028

  • 4.1. Allergan Overview
    • 4.1.1. Allergan: Ophthalmic Product Portfolio
    • 4.1.2. Allergan: Late Stage Ophthalmic Product Pipeline
    • 4.1.3. Allergan: Ophthalmic Revenue Forecast 2018-2028
    • 4.1.4. Allergan: SWOT Analysis
  • 4.2. Pfizer Overview
    • 4.2.1. Pfizer: Ophthalmic Product Portfolio
    • 4.2.2. Pfizer: Ophthalmic Product Pipeline
    • 4.2.3. Pfizer: Revenue Forecast 2018-2028
    • 4.2.4. Pfizer: SWOT Analysis
  • 4.3. Regeneron Overview
    • 4.3.1. Regeneron: Ophthalmic Product Portfolio
    • 4.3.2. Regeneron: Ophthalmic Product Pipeline
    • 4.3.3. Regeneron: Revenue Forecast 2018-2028
    • 4.3.4. FDA Approves Zaltrap (aflibercept)
    • 4.3.5. Eylea/Zaltrap and the Davis-Smyth Patent Agreements
    • 4.3.6. Regeneron: SWOT Analysis
  • 4.4. Akorn Overview
    • 4.4.1. Akorn: Ophthalmic Product Portfolio
    • 4.4.2. Akorn: Revenue Forecast 2018-2028
    • 4.4.3. Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2018-2028

  • 5.1. Bayer Overview
    • 5.1.1. Bayer: Ophthalmic Product Pipeline
    • 5.1.2. Eylea: non-US Sales Forecast 2018-2028
    • 5.1.3. Bayer: Revenue Forecast 2018-2028
  • 5.2. Novartis (including Alcon) Overview
    • 5.2.1. Novartis: Ophthalmic Product Portfolio
    • 5.2.2. Novartis: Ophthalmic Product Pipeline
    • 5.2.3. Novartis: Revenue Forecast 2018-2028
    • 5.2.4. Novartis: SWOT Analysis
  • 5.3. Roche Overview
    • 5.3.1. Roche: Ophthalmic Product Portfolio
    • 5.3.2. Roche: Ophthalmic Product Pipeline
    • 5.3.3. Roche: Revenue Forecast 2018-2028
    • 5.3.4. Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2018-2028

  • 6.1. Santen Overview
    • 6.1.1. Santen: Ophthalmic Product Portfolio
    • 6.1.2. Santen: Ophthalmic Product Pipeline
    • 6.1.3. Santen: Revenue Forecast 2018-2028
    • 6.1.4. Santen: SWOT Analysis
  • 6.2. Senju Overview
    • 6.2.1. Senju: Ophthalmic Product Portfolio
    • 6.2.2. Senju: Ophthalmic Product Pipeline
    • 6.2.3. Senju: Revenue Forecast 2018-2028
    • 6.2.4. Senju: SWOT Analysis
  • 6.3. Valeant Overview
    • 6.3.1. Valeant: Ophthalmic Product Portfolio
    • 6.3.2. Valeant: Ophthalmic Product Pipeline
    • 6.3.3. Valeant: Revenue Forecast 2018-2028
    • 6.3.4. Valeant: SWOT Analysis

7. Emerging Ophthalmic Drug Manufacturers in 2017

  • 7.1. Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2017
  • 7.2. Acucela
  • 7.3. Aerie Pharmaceuticals
  • 7.4. Aerpio Therapeutics: Developing AKB 9778
  • 7.5. Alimera Sciences
  • 7.5.1. Iluvien: Increasing Geographical Reach and Increasing Sales
  • 7.5.2. NADPH Oxidase Inhibitors Offer Potential for Dry AMD
  • 7.6. Amakem
  • 7.7. Ampio Pharmaceuticals
  • 7.8. Chengdu Kanghong Pharmaceutical
  • 7.9. Eleven Biotherapeutics
  • 7.10. EyeGate Pharmaceuticals
  • 7.11. Gene Signal
    • 7.11.1. Aganirsen: Preventing Corneal Graft Rejection
  • 7.12. Icon Bioscience
  • 7.13. MacuCLEAR
    • 7.13.1. MC 1101: a Potential Therapy for Dry AMD
  • 7.14. Neurotech
  • 7.15. Omeros
  • 7.16. OphthaliX (Can-Fite BioPharma)
  • 7.17. Ophthotech
    • 7.17.1. Fovista: Potential Game-Changer in AMD
    • 7.17.2. Fovista: Significant Improvement on Lucentis in Phase II Trials
    • 7.17.3. Zimura: Complement C5 Inhibitor
  • 7.18. Otsuka Pharmaceutical
  • 7.19. pSivida Corp.
  • 7.20. RXi Pharmaceuticals: Will Bevasiranib Resume Development?
  • 7.21. Shire
    • 7.21.1. Lifitegrast (SHP606) for Dry Eye
    • 7.21.2. Premiplex (SHP607): Preventing Retinopathy of Prematurity
  • 7.22. ThromboGenics
    • 7.22.1. Jetrea (ocriplasmin)
    • 7.22.2. ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2018-2028

  • 8.1. Porter's Five Forces Analysis of the Ophthalmic Drugs Market
    • 8.1.1. Rivalry Among Competitors [Medium]
    • 8.1.2. Threat of New Entrants [Low]
    • 8.1.3. Power of Suppliers [Low]
    • 8.1.4. Power of Buyers [Medium]
    • 8.1.5. Threat of Substitutes [Medium]

9. Conclusions

  • 9.1. Ophthalmic Pharmaceuticals: A Growing Niche Market
  • 9.2. The World Ophthalmic Drugs Market in 2017
    • 9.2.1. Leading Ophthalmic Drugs Market Segments
    • 9.2.2. Leading Ophthalmic Drugs
    • 9.2.3. Leading Ophthalmic Drugs Companies
  • 9.3. World Ophthalmic Drugs Market Forecast 2018-2028
  • 9.4. The Future of the Ophthalmic Drugs Market?
    • 9.4.1. Increasing Revenue Concentration among Specialist Companies
    • 9.4.2. The Rise of Generics
    • 9.4.3. Small Companies Can Have a Big Impact
    • 9.4.4. What Will Succeed in the Ophthalmic Drugs Market?
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: ICD 10 Classification of Visual Impairment, 2015
  • Table 2.2: Drug Treatments for Glaucoma, 2017
  • Table 2.3: Drug Treatments for AMD, 2017
  • Table 2.4: Drug Treatments for Ocular Allergy, 2017
  • Table 2.5: Drug Treatments for Ocular Inflammatory Disease, 2017
  • Table 2.6: Selected Drug Treatments for Eye Infections, 2017
  • Table 2.7: Clinical Trial Phases
  • Table 3.1: World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2017
  • Table 3.2: World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028
  • Table 3.3: Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2017
  • Table 3.4: Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2017
  • Table 3.5: Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2017
  • Table 3.6: World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2017-2028
  • Table 3.7: Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
  • Table 3.8: Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 3.9: Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 3.10: Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 3.11: Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2028
  • Table 3.12: Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2017, 2023 and 2028
  • Table 4.1: Allergan: Overview, 2017
  • Table 4.2: Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2016 and 2017
  • Table 4.3: Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.4: Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.5: Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.6: Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.7: Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.8: Allergan: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 4.9: Pfizer: Overview, 2017
  • Table 4.10: Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.11: Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.12: Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.13: Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 4.14: Regeneron: Overview, 2017
  • Table 4.15: Regeneron: Eylea Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 4.16: Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.17: Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.18: Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 4.19: Akorn: Overview, 2017
  • Table 4.20: Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 4.21: Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 4.22: Akorn: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 5.1: Bayer: Overview, 2017
  • Table 5.2: Bayer: Eylea Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.3: Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.4: Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 5.5: Novartis: Overview, 2017
  • Table 5.6: Novartis: Lucentis Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.7: Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.8: Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 5.9: Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 5.11: Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.12: Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 5.13: Novartis: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 5.14: Roche: Overview, 2017
  • Table 5.15: Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 5.16: Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.17: Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.18: Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 5.19: Roche: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 6.1: Santen: Overview, 2017
  • Table 6.2: Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2017
  • Table 6.3: Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2017-2028
  • Table 6.4: Santen: Hyalein Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.5: Santen: Cosopt Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.6: Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.7: Santen: Diquas Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.8: Santen: Cravit Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.9: Santen: Alesion Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.10: Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.11: Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 6.12: Santen: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 6.13: Senju: Overview, 2017
  • Table 6.14: Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2017
  • Table 6.15: Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.16: Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 6.17: Senju: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 6.18: Valeant: Overview, 2017
  • Table 6.19: Valeant: Lotemax Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.20: Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 6.21: Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2017-2028
  • Table 6.22: Valeant: Ophthalmic Drugs Market SWOT Analysis, 2018-2028
  • Table 7.1: Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country
  • Table 9.1: Leading Ophthalmic Drugs Manufacturers: Revenues ($m), Market Share (%), 2018

List of Figures

  • Figure 1.1: Global Causes of Visual Impairment (% of cases), 2017
  • Figure 1.2: World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015 and 2026
  • Figure 1.3: Global Ophthalmic Drugs Market Segmentation Overview, 2017
  • Figure 2.1: Estimated Global Blindness and Visual Impairment (% of people), 2015
  • Figure 2.2: Estimated Global Prevalence of Visual Impairment (millions of people), 2015
  • Figure 2.3: Global Causes of Visual Impairment (% of cases), 2015
  • Figure 2.4: Global Causes of Blindness (% of cases), 2015
  • Figure 2.5: Classification of Glaucoma, 2017
  • Figure 3.1: World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2017
  • Figure 3.2: World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017
  • Figure 3.3: World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR (%), 2018-2028
  • Figure 3.4: Top 9 Ophthalmic Drugs: Revenues ($m), 2017
  • Figure 3.5: Top 9 Ophthalmic Drugs: Market Share (%), 2017
  • Figure 3.6: Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2017
  • Figure 3.7: Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2017
  • Figure 3.8: Retinal Disorders Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.9: Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2017-2028
  • Figure 3.10: Glaucoma Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.11: Dry Eye Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.12: Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2017-2028
  • Figure 3.13: World Ophthalmic Drugs Market: Market Share (%) by Segment, 2017
  • Figure 3.14: World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2023
  • Figure 3.15: World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2028
  • Figure 3.16: World Ophthalmic Drugs Market: Drivers and Restraints, 2018-2028
  • Figure 4.1: Allergan: Restasis Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.2: Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.3: Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.4: Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.5: Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 4.6: Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2017-2028
  • Figure 4.7: Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.8: Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 4.9: Regeneron: Eylea Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.10: Regeneron: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.11: Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 4.12: Akorn: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 4.13: Akorn: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 5.1: Bayer: Eylea Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.2: Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.3: Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 5.4: Novartis: Lucentis Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.5: Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.6: Novartis: Vigamox Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.7: Novartis: Azopt Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.8: Novartis: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.9: Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 5.10: Roche: Lucentis Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.11: Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2017-2028
  • Figure 5.12: Roche: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 5.13: Roche: Ophthalmic Drugs Revenue and Market Share (%), 2017-2028
  • Figure 6.1: Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2017
  • Figure 6.2: Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2017
  • Figure 6.3: Santen: Eylea Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.4: Santen: Hyalein Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.5: Santen: Cosopt Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.6: Santen: Tapros/Taflotan Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.7: Santen: Diquas Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.8: Santen: Cravit Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.9: Santen: Alesion Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.10: Santen: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.11: Santen: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 6.12: Senju: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.13: Senju: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 6.14: Valeant: Lotemax Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.15: Valeant: Ophthalmic Drugs Revenue ($m) and AGR (%), 2017-2028
  • Figure 6.16: Valeant: Ophthalmic Drugs Market Share (%), 2017-2028
  • Figure 7.1: Gene Signal: Ophthalmic Drug Pipeline Progress
  • Figure 7.2: Ophthotech: Ophthalmic Drug Pipeline Progress
  • Figure 7.3: Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress
  • Figure 7.4: Shire: Ophthalmic Drug Pipeline Progress
  • Figure 8.1: Porter's Five Forces Analysis of the Ophthalmic Drugs Market, 2018-2028

COMPANIES LISTED

  • Abbott Laboratories (Abbott)
  • Abbvie
  • Actavis
  • Acucela
  • Advanced Vision Research (acquired by Akorn)
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Akorn Pharmaceuticals
  • Alcon (subsidiary of Novartis)
  • Alimera Sciences
  • Allergan
  • Allegro Ophthalmics
  • Altheos
  • Amakem
  • Ampio Pharma
  • Asahi Glass
  • AstraZeneca
  • Aton Pharma (acquired by Valeant)
  • Banyu Pharmaceutical (part of Merck)
  • Bausch and Lomb (subsidiary of Valeant)
  • Bayer
  • Bayer Yakuhin (Japanese subsidiary of Bayer)
  • BioDiem
  • Bicycle Therapeutics
  • Biogen Idec
  • BioInvent International
  • Biovail Corporation (part of Valeant)
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Chengdu Kanghong Pharmaceutical
  • Chiron Corportation (part of Novartis)
  • Chugai Pharmaceutical (part of Roche)
  • CIBA VISION (part of Novartis)
  • Ciba-Geigy (part of Novartis)
  • Colby Pharmaceutical Company (Colby)
  • CoMentis
  • Daiichi Sankyo
  • Eleven Biotherapeutics
  • Eli Lilly and Company (Lilly)
  • EyeGate Pharmaceuticals
  • Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
  • Fougera Pharmaceuticals (acquired by Novartis)
  • Gene Signal
  • Genentech (subsidiary of Roche)
  • Genzyme (subsidiary of Sanofi)
  • Gilead Sciences
  • GSK
  • ICN Pharmaceuticals (original Valeant company)
  • Icon Bioscience
  • Inamed Corporation (subsidiary of Allergan)
  • Inception Sciences, Inc.
  • InSite Vision
  • Inspire Pharmaceuticals (acquired by Merck)
  • ISTA Pharmaceuticals (part of Valeant)
  • Jerini AG
  • Jerini Ophthalmic (part of Jerini AG)
  • Johnson & Johnson
  • Kestrel Ophthalmics
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Lpath
  • MacuCLEAR
  • MacuSIGHT, Inc.
  • MAP Pharmaceuticals (acquired by Allergan)
  • Meda
  • Medicis Corporation (acquired by Valeant)
  • Merck & Co. (Merck)
  • MerLion Pharmaceuticals
  • MSD K.K. (part of Merck)
  • Mylan Pharmaceuticals
  • Mystic Pharmaceuticals
  • Neurotech
  • NicOx
  • Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
  • NovaBay Pharmaceuticals
  • Novagali Pharma (acquired by Santen)
  • Novartis
  • Novo (subsidiary of Novo Nordisk)
  • Novo Nordisk
  • Oakwood Laboratories
  • OcuSciences
  • Omeros
  • Onyx Pharmaceuticals
  • OphthaliX (part-owned by Can-Fite BioPharma)
  • Ophthotech
  • OPKO Health
  • Ora
  • OSI Pharmaceuticals
  • Othera Pharmaceuticals (acquired by Colby)
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • OXiGENE
  • Parke-Davis (subsidiary of Pfizer)
  • PDL BioPharma
  • Pfizer
  • Pharmacia (acquired by Pfizer)
  • Potentia Pharmaceuticals
  • Premacure
  • Procter & Gamble
  • pSivida
  • Quark Pharmaceuticals
  • Reckitt Benckiser
  • Regeneron
  • RetroSense Therapeutics
  • ReVision Therapeutics
  • Roche
  • RXi Pharmaceuticals
  • Sandoz (part of Novartis)
  • Sanofi
  • Santen Pharmaceutical Co. (Santen)
  • SARcode Bioscience
  • Schering-Plough (part of Merck)
  • Senju
  • Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
  • Senju USA Inc. (subsidiary of Senju)
  • Shire
  • Sirion Therapeutics
  • Sirna Therapeutics
  • Sirnaomics
  • SkinMedica (subsidiary of Allergan)
  • Spark Therapeutics
  • Symphony ViDA
  • Takeda Pharmaceutical
  • Teva
  • The Patent Board
  • ThromboGenics
  • Upjohn (acquired by Pfizer through Pharmacia)
  • Valeant Pharmaceuticals
  • Ventana Medical Systems (acquired by Roche)
  • Versant Ventures
  • Warburg Pincus LLC
  • Warner-Lambert (acquired by Pfizer)
  • Watson Pharmaceuticals
  • Wyeth Pharmaceuticals (part of Pfizer)

List of Other Organizations Mentioned in the Report:

  • A*STAR Institute for Infocomm Research (Singapore)
  • American Academy of Ophthalmology (AAO)
  • American Diabetes Association
  • American Society of Retina Specialists (ASRS)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Council of Europe
  • Emory University
  • European Medicines Agency (EMA)
  • Foundation Fighting Blindness (FFB) (US)
  • Health Canada
  • Institute of Experimental Medicine (Russia)
  • Institute of Ocular Pharmacology, Texas A&M (US)
  • Institute of Ophthalmology, University College London (UK)
  • Intellectual Property Appellate Board (India)
  • International Diabetes Federation
  • Internet Archive
  • Japan Patent Office (JPO)
  • Mayo Clinic
  • Ministry of Health, Labour and Welfare (MHLW) (Japan)
  • Monash University
  • National Eye Institute (NEI) (US)
  • National Health Service (NHS) (UK)
  • National Institute for Health and Care Excellence (NICE) (UK)
  • NHS Scotland
  • Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
  • Novartis Venture Funds (NVF) (part of Novartis)
  • Ophthalmology External Research Unit (part of Pfizer)
  • Ophthrisi (GSK research unit)
  • Rinat (Pfizer research unit)
  • Texas Emerging Technology Fund
  • Therapeutic Goods Administration (TGA) (Australia)
  • Tokyo University of Science
  • United States Food and Drug Administration (FDA)
  • University of Florida
  • University of Kentucky
  • University of Melbourne
  • University of Michigan
  • US Preventive Services Task Force (USPSTF)
  • US Securities and Exchange Commission (SEC)
  • World Health Organization (WHO)
Back to Top